Premium
Influence of Age Upon Ifosfamide‐Induced Nephrotoxicity
Author(s) -
McCune Jeannine S.,
Friedman Debra L.,
Schuetze Scott,
Blough David,
Magbulos Madonna,
Hawkins Douglas S.
Publication year - 2004
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.20011
Subject(s) - ifosfamide , nephrotoxicity , medicine , cumulative dose , toxicity , chemotherapy , urology , cisplatin
Background Ifosfamide‐induced nephrotoxicity is well recognized in children, although it has also been reported in adults. Whether ifosfamide nephrotoxicity is more common in children than in adults is not known. Procedure Medical records of adults and children diagnosed with sarcoma whom received ifosfamide with a cumulative dose >20 g/m 2 were evaluated. Twenty‐five children (≤18‐years of age) and 28 adults were identified. Results National Cancer Institute Common Toxicity Criteria grade 3–4 ifosfamide‐induced nephrotoxicity was present in 24 and 17% of children and adults, respectively ( P = 0.58). Cumulative ifosfamide doses were similar between the two populations, with the median (range) of 70.2 g/m 2 (22.4–72) for children and 59 g/m 2 (20.8–146) for adults ( P = 0.25). Logistic regression analysis indicated that neither age or cumulative ifosfamide dose were associated with grade 3–4 ifosfamide‐induced nephrotoxicity ( P = 0.36). Conclusions Children and adults receiving >20 g/m 2 of ifosfamide have similar susceptibility to ifosfamide‐induced nephrotoxicity. Factors other than age and cumulative dose should be considered for understanding the inter‐individual variation in nephrotoxicity. © 2004 Wiley‐Liss, Inc.